{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T22:54:06Z","timestamp":1774047246462,"version":"3.50.1"},"reference-count":117,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100019252","name":"Centro Interdisciplinar de Ci\u00eancias Sociais","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019252","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Fundacao para a Ciencia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDB\/00709\/2020"],"award-info":[{"award-number":["UIDB\/00709\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.cca.2026.120949","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T16:40:49Z","timestamp":1773074449000},"page":"120949","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["From bench to bedside: translating the histone deacetylase inhibitors into prostate cancer therapies"],"prefix":"10.1016","volume":"587","author":[{"given":"Sandra Moreira","family":"Rocha","sequence":"first","affiliation":[]},{"given":"Mafalda Baptista","family":"Br\u00e1s","sequence":"additional","affiliation":[]},{"given":"Bruno J.","family":"Pereira","sequence":"additional","affiliation":[]},{"given":"Cl\u00e1udio J.","family":"Maia","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.cca.2026.120949_bb0005","first-page":"451","article-title":"Global cancer statistics 2022: the trends projection analysis","volume":"10","author":"Chhikara","year":"2023","journal-title":"Chem. Biol. Lett."},{"issue":"2","key":"10.1016\/j.cca.2026.120949_bb0010","first-page":"69","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J. Clin."},{"issue":"11","key":"10.1016\/j.cca.2026.120949_bb0015","doi-asserted-by":"crossref","first-page":"e645","DOI":"10.1016\/S1470-2045(19)30404-8","article-title":"Core elements of national cancer control plans: a tool to support plan development and review","volume":"20","author":"Oar","year":"2019","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.cca.2026.120949_bb0020","first-page":"63","article-title":"Epidemiology of prostate cancer","volume":"10","author":"Rawla","year":"2019"},{"issue":"17\u201318","key":"10.1016\/j.cca.2026.120949_bb0025","first-page":"1105","article-title":"Genetics and biology of prostate cancer","volume":"32","author":"W. G","year":"2018","journal-title":"Genes Dev."},{"issue":"2","key":"10.1016\/j.cca.2026.120949_bb0030","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s40610-018-0095-9","article-title":"Epigenetic regulation in prostate Cancer progression","volume":"4","author":"Ruggero","year":"2018","journal-title":"Curr. Mol. Biol. Reports"},{"issue":"1\u20132","key":"10.1016\/j.cca.2026.120949_bb0035","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1615\/CritRevOncog.2015012997","article-title":"Histone deacetylases and mechanisms of regulation of gene expression (histone deacetylases in cancer)","volume":"20","author":"Chen","year":"2015","journal-title":"Crit. Rev. Oncog."},{"issue":"11","key":"10.1016\/j.cca.2026.120949_bb0040","first-page":"15030","article-title":"Effect of histone deacetylase on prostate carcinoma","volume":"8","author":"Y","year":"2015","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.cca.2026.120949_bb0045","series-title":"Epigenetics Pathol. Explor. Connect. between Genet. Mech. Dis. Expr.","first-page":"143","article-title":"Roles of histone deacetylases in epigenetic regulation: emerging paradigms from studies with inhibitors","author":"Delcuve","year":"2013"},{"key":"10.1016\/j.cca.2026.120949_bb0050","article-title":"Potential of histone deacetylase inhibitors in the control and regulation of prostate, breast and ovarian cancer","volume":"10","author":"Das Pramanik","year":"2022","journal-title":"Front. Chem."},{"issue":"5","key":"10.1016\/j.cca.2026.120949_bb0055","article-title":"Anatomy and histology of the human and murine prostate","volume":"8","author":"M","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"8","key":"10.1016\/j.cca.2026.120949_bb0060","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/00000478-198808000-00003","article-title":"Normal histology of the prostate","volume":"12","author":"JE","year":"1988","journal-title":"Am. J. Surg. Pathol."},{"issue":"6","key":"10.1016\/j.cca.2026.120949_bb0065","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.urology.2011.07.1395","article-title":"The McNeal prostate: a review","volume":"78","author":"SH","year":"2011","journal-title":"Urology"},{"issue":"2","key":"10.1016\/j.cca.2026.120949_bb0070","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/PAS.0b013e31812f7b27","article-title":"Anterior-predominant prostatic tumors: zone of origin and pathologic outcomes at radical prostatectomy","volume":"32","author":"HA","year":"2008","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.cca.2026.120949_bb0075","series-title":"Biology of Prostate Cancer","author":"Oh","year":"2003"},{"issue":"3","key":"10.1016\/j.cca.2026.120949_bb0080","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.ecl.2011.05.012","article-title":"Overview of prostate anatomy, histology, and pathology","volume":"40","author":"CH","year":"2011","journal-title":"Endocrinol. Metab. Clin. North Am."},{"issue":"5","key":"10.1016\/j.cca.2026.120949_bb0085","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1016\/j.juro.2008.01.017","article-title":"Central zone carcinoma of the prostate gland: a distinct tumor type with poor prognostic features","volume":"179","author":"RJ","year":"2008","journal-title":"J. Urol."},{"issue":"1","key":"10.1016\/j.cca.2026.120949_bb0090","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/pros.2990020105","article-title":"The zonal anatomy of the prostate","volume":"2","author":"JE","year":"1981","journal-title":"Prostate"},{"issue":"6 Pt A","key":"10.1016\/j.cca.2026.120949_bb0095","first-page":"1238","article-title":"The molecular and cellular origin of human prostate cancer","volume":"1863","author":"JR","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.cca.2026.120949_bb0100","unstructured":"P. W. O. Barbara Young, Wheater's functional histology: a text and colour atlas, 6th edition., vol. chapter 18. Churchill Livingston\/Elservier."},{"issue":"5","key":"10.1016\/j.cca.2026.120949_bb0105","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/s41374-019-0352-4","article-title":"Castration-induced stromal remodeling disrupts the reconstituted prostate epithelial structure","volume":"100","author":"S","year":"2020","journal-title":"Lab. Invest."},{"issue":"1","key":"10.1016\/j.cca.2026.120949_bb0110","first-page":"1","article-title":"Prostate epithelial cell differentiation and its relevance to the understanding of prostate cancer therapies","volume":"108","author":"RM","year":"2005","journal-title":"Clin. Sci. (Lond.)"},{"issue":"4","key":"10.1016\/j.cca.2026.120949_bb0115","first-page":"273","article-title":"Neuroendocrine differentiation of prostate cancer: a review","volume":"2","author":"Parimi","year":"2014","journal-title":"Am. J. Clin. Exp. Urol."},{"issue":"1","key":"10.1016\/j.cca.2026.120949_bb0120","first-page":"183","article-title":"The tumor microenvironment in prostate cancer: elucidating molecular pathways for therapy development","volume":"4","author":"PG","year":"2012","journal-title":"Cancer Manag. Res."},{"issue":"8","key":"10.1016\/j.cca.2026.120949_bb0125","article-title":"Cellular constituents of the prostate stroma: key contributors to prostate cancer progression and therapy resistance","volume":"8","author":"C","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"3","key":"10.1016\/j.cca.2026.120949_bb0130","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.fertnstert.2016.07.1101","article-title":"Seminal fluid and fertility in women","volume":"106","author":"SA","year":"2016","journal-title":"Fertil. Steril."},{"issue":"4","key":"10.1016\/j.cca.2026.120949_bb0135","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.jsbmb.2004.10.004","article-title":"Sex steroid hormone metabolism and prostate cancer","volume":"92","author":"Soronen","year":"2004","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"1","key":"10.1016\/j.cca.2026.120949_bb0140","first-page":"35","article-title":"Androgen action in the prostate gland","volume":"64","author":"N","year":"2012","journal-title":"Minerva Urol. Nefrol."},{"issue":"3","key":"10.1016\/j.cca.2026.120949_bb0145","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/ncb2697","article-title":"Lineage analysis of basal epithelial cells reveals their unexpected plasticity and supports a cell-of-origin model for prostate cancer heterogeneity","volume":"15","author":"W.","year":"2013","journal-title":"Nat. Cell Biol."},{"issue":"6","key":"10.1016\/j.cca.2026.120949_bb0150","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1073\/pnas.0913873107","article-title":"Basal epithelial stem cells are efficient targets for prostate cancer initiation","volume":"107","author":"Lawson","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5","key":"10.1016\/j.cca.2026.120949_bb0155","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.celrep.2014.08.002","article-title":"Luminal cells are Favored as the cell of origin for prostate Cancer","volume":"8","author":"Wang","year":"2014","journal-title":"Cell Rep."},{"issue":"7263","key":"10.1016\/j.cca.2026.120949_bb0160","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature08361","article-title":"A luminal epithelial stem cell that is a cell of origin for prostate cancer","volume":"461","author":"W.","year":"2009","journal-title":"Nature"},{"issue":"18","key":"10.1016\/j.cca.2026.120949_bb0165","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1101\/gad.1965810","article-title":"Molecular genetics of prostate cancer: new prospects for old challenges","volume":"24","author":"Shen","year":"2010","journal-title":"Genes Dev."},{"issue":"8","key":"10.1016\/j.cca.2026.120949_bb0170","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.5858\/2007-131-1257-PINRA","article-title":"Prostatic intraepithelial neoplasia: recent advances","volume":"131","author":"Ayala","year":"2007","journal-title":"Arch. Pathol. Lab. Med."},{"issue":"2","key":"10.1016\/j.cca.2026.120949_bb0175","first-page":"156","article-title":"Prostatic preneoplasia and beyond","volume":"1785","author":"J.","year":"2008","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.cca.2026.120949_bb0180","series-title":"Prostate Cancer","first-page":"29","article-title":"The pathogenesis of prostate Cancer","author":"Murray","year":"2021"},{"issue":"9","key":"10.1016\/j.cca.2026.120949_bb0185","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1097\/00000478-199809000-00005","article-title":"Histology and cellular kinetics of prostatic atrophy","volume":"22","author":"R.","year":"1998","journal-title":"Am. J. Surg. Pathol."},{"issue":"2","key":"10.1016\/j.cca.2026.120949_bb0190","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1439-0272.2007.00831.x","article-title":"Proliferative inflammatory atrophy: a background lesion of prostate cancer?","volume":"40","author":"Woenckhaus","year":"2008","journal-title":"Andrologia"},{"issue":"1","key":"10.1016\/j.cca.2026.120949_bb0195","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1148\/radiology.172.1.2472644","article-title":"Prostatic carcinoma and benign prostatic hyperplasia: correlation of high-resolution MR and histopathologic findings","volume":"172","author":"ML","year":"1989","journal-title":"Radiology"},{"issue":"2","key":"10.1016\/j.cca.2026.120949_bb0200","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1148\/radiology.189.2.8210358","article-title":"Current role of MR imaging in the staging of adenocarcinoma of the prostate","volume":"189","author":"ML","year":"1993","journal-title":"Radiology"},{"issue":"7","key":"10.1016\/j.cca.2026.120949_bb0205","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/nrurol.2009.123","article-title":"Prostate kallikrein markers in diagnosis, risk stratification and prognosis","volume":"6","author":"Ulmert","year":"2009","journal-title":"Nat. Rev. Urol."},{"issue":"3","key":"10.1016\/j.cca.2026.120949_bb0210","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/BF00132746","article-title":"The role of proteolytic enzymes in cancer invasion and metastasis","volume":"10","author":"MJ","year":"1992","journal-title":"Clin. Exp. Metastasis"},{"issue":"2","key":"10.1016\/j.cca.2026.120949_bb0215","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/PAS.0000000000000530","article-title":"The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system","volume":"40","author":"JI","year":"2016","journal-title":"Am. J. Surg. Pathol."},{"issue":"3","key":"10.1016\/j.cca.2026.120949_bb0220","doi-asserted-by":"crossref","first-page":"661","DOI":"10.31557\/APJCP.2019.20.3.661","article-title":"Prostatic adenocarcinoma: a grading from Gleason to the new grade-group system: a historical and critical review","volume":"20","author":"MA","year":"2019","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.cca.2026.120949_bb0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-319-95693-0_1","article-title":"Brief overview of prostate cancer statistics, grading, diagnosis and treatment strategies","volume":"1095","author":"Schatten","year":"2018","journal-title":"Adv. Exp. Med. Biol."},{"issue":"4","key":"10.1016\/j.cca.2026.120949_bb0230","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1023\/A:1006121219097","article-title":"Epigenetic mechanisms for progression of prostate cancer","volume":"17","author":"PS","year":"1998","journal-title":"Cancer Metastasis Rev."},{"issue":"10","key":"10.1016\/j.cca.2026.120949_bb0235","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1093\/nar\/27.10.2099","article-title":"Isolation of CpG islands from large genomic clones","volume":"27","author":"Cross","year":"1999","journal-title":"Nucleic Acids Res."},{"issue":"2","key":"10.1016\/j.cca.2026.120949_bb0240","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/iju.14406","article-title":"Epigenetic modifications in prostate cancer","volume":"28","author":"Sugiura","year":"2021","journal-title":"Int. J. Urol."},{"issue":"1","key":"10.1016\/j.cca.2026.120949_bb0245","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/npp.2012.112","article-title":"DNA methylation and its basic function","volume":"38","author":"Moore","year":"2013","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.cca.2026.120949_bb0250","article-title":"TET proteins and the control of cytosine demethylation in cancer","volume":"7","author":"L","year":"2015","journal-title":"Genome Med."},{"issue":"7","key":"10.1016\/j.cca.2026.120949_bb0255","doi-asserted-by":"crossref","first-page":"486","DOI":"10.2174\/138920211797904061","article-title":"Aberrant DNA methylation and prostate cancer","volume":"12","author":"S","year":"2011","journal-title":"Curr. Genomics"},{"issue":"9","key":"10.1016\/j.cca.2026.120949_bb0260","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1038\/bjc.2014.463","article-title":"Methylated glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer","volume":"111","author":"KL","year":"2014","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.cca.2026.120949_bb0265","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.3892\/or.2016.5000","article-title":"Epigenetic modulation of AR gene expression in prostate cancer DU145 cells with the combination of sodium butyrate and 5\u2032-Aza-2\u2032-deoxycytidine","volume":"36","author":"B","year":"2016","journal-title":"Oncol. Rep."},{"issue":"9","key":"10.1016\/j.cca.2026.120949_bb0270","first-page":"822","article-title":"Role of RASSF1A hypermethylation in prostate cancer","volume":"13","author":"YC","year":"2007","journal-title":"Zhonghua Nan Ke Xue"},{"issue":"1","key":"10.1016\/j.cca.2026.120949_bb0275","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/15592294.2016.1261786","article-title":"LINE-1 methylation status in prostate cancer and non-neoplastic tissue adjacent to tumor in association with mortality","volume":"12","author":"V","year":"2017","journal-title":"Epigenetics"},{"issue":"1","key":"10.1016\/j.cca.2026.120949_bb0280","first-page":"1","article-title":"Global DNA hypomethylation in prostate cancer development and progression: a systematic review","volume":"18","author":"R","year":"2015","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"21","key":"10.1016\/j.cca.2026.120949_bb0285","doi-asserted-by":"crossref","first-page":"8954","DOI":"10.1158\/0008-5472.CAN-07-6088","article-title":"DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity","volume":"68","author":"S","year":"2008","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.cca.2026.120949_bb0290","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.yexmp.2013.03.006","article-title":"Deregulated expression of urokinase and its inhibitor type 1 in prostate cancer cells: role of epigenetic mechanisms","volume":"94","author":"A","year":"2013","journal-title":"Exp. Mol. Pathol."},{"issue":"7","key":"10.1016\/j.cca.2026.120949_bb0295","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2174\/156800905774574011","article-title":"Hypomethylation of urokinase (uPA) promoter in breast and prostate cancer: prognostic and therapeutic implications","volume":"5","author":"P","year":"2005","journal-title":"Curr. Cancer Drug Targets"},{"issue":"3","key":"10.1016\/j.cca.2026.120949_bb0300","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1158\/1078-0432.1028.11.3","article-title":"Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancer","volume":"11","author":"Ogishima","year":"2005","journal-title":"Clin. Cancer Res."},{"issue":"16","key":"10.1016\/j.cca.2026.120949_bb0305","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.1158\/1078-0432.CCR-04-2545","article-title":"Cytochrome P450 1B1 is overexpressed and regulated by hypomethylation in prostate cancer","volume":"11","author":"T","year":"2005","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.cca.2026.120949_bb0310","doi-asserted-by":"crossref","DOI":"10.3390\/life11111251","article-title":"Promoter demethylation upregulates STEAP1 gene expression in human prostate cancer: in vitro and in silico analysis","volume":"11","author":"Rocha","year":"2021","journal-title":"Life"},{"key":"10.1016\/j.cca.2026.120949_bb0315","doi-asserted-by":"crossref","unstructured":"C. Macedo-Silva, R. Benedetti, F. Ciardiello, S. Cappabianca, C. Jer\u00f3nimo, and L. Altucci, \u201cEpigenetic mechanisms underlying prostate cancer radioresistance,\u201d Clin. Epigenetics 2021, vol. 13, no. 1, pp. 1\u201315, Jun. 2021, doi:https:\/\/doi.org\/10.1186\/S13148-021-01111-8.","DOI":"10.1186\/s13148-021-01111-8"},{"issue":"5\u20136","key":"10.1016\/j.cca.2026.120949_bb0320","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1615\/CritRevOncog.2017020964","article-title":"Epigenetic modifications and modulators in prostate Cancer","volume":"22","author":"Cimadamore","year":"2017","journal-title":"Crit. Rev. Oncog."},{"issue":"1","key":"10.1016\/j.cca.2026.120949_bb0325","article-title":"Global analysis of H3K27me3 as an epigenetic marker in prostate cancer progression","volume":"17","author":"M","year":"2017","journal-title":"BMC Cancer"},{"issue":"34","key":"10.1016\/j.cca.2026.120949_bb0330","doi-asserted-by":"crossref","first-page":"23413","DOI":"10.18632\/oncotarget.25182","article-title":"A new metabolic gene signature in prostate cancer regulated by JMJD3 and EZH2","volume":"9","author":"D.","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.cca.2026.120949_bb0335","article-title":"The emerging role of histone lysine demethylases in prostate cancer","volume":"11","author":"C. F","year":"2012","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.cca.2026.120949_bb0340","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1042\/BJ20100980","article-title":"Procyanidin B3, an inhibitor of histone acetyltransferase, enhances the action of antagonist for prostate cancer cells via inhibition of p300-dependent acetylation of androgen receptor","volume":"433","author":"C.","year":"2011","journal-title":"Biochem. J."},{"issue":"11","key":"10.1016\/j.cca.2026.120949_bb0345","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1021\/acschembio.6b01035","article-title":"Identifying dysregulated epigenetic enzyme activity in castrate-resistant prostate cancer development","volume":"12","author":"L.","year":"2017","journal-title":"ACS Chem. Biol."},{"issue":"11","key":"10.1016\/j.cca.2026.120949_bb0350","first-page":"1","article-title":"Curcumin against prostate cancer: current evidence","volume":"10","author":"D","year":"2020","journal-title":"Biomolecules"},{"issue":"2","key":"10.1016\/j.cca.2026.120949_bb0355","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2174\/157340606776056133","article-title":"Curcumin is an inhibitor of p300 histone acetylatransferase","volume":"2","author":"M.","year":"2006","journal-title":"Med. Chem."},{"issue":"5","key":"10.1016\/j.cca.2026.120949_bb0360","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.132306","article-title":"TNF-\u03b1 regulates diabetic macrophage function through the histone acetyltransferase MOF","volume":"5","author":"denDekker","year":"2020","journal-title":"JCI Insight"},{"issue":"2","key":"10.1016\/j.cca.2026.120949_bb0365","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines8020022","article-title":"Understanding failure and improving treatment using HDAC inhibitors for prostate cancer","volume":"8","author":"Z. Rana","year":"2020","journal-title":"Biomedicines"},{"issue":"6","key":"10.1016\/j.cca.2026.120949_bb0370","doi-asserted-by":"crossref","first-page":"300","DOI":"10.4161\/epi.3.6.7273","article-title":"The role of histone deacetylases in prostate Cancer","volume":"3","author":"Abbas","year":"2008","journal-title":"Epigenetics"},{"issue":"3","key":"10.1016\/j.cca.2026.120949_bb0375","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/sj.bjc.6604199","article-title":"Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy","volume":"98","author":"Weichert","year":"2008","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.cca.2026.120949_bb0380","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.canlet.2008.10.047","article-title":"HDAC expression and clinical prognosis in human malignancies","volume":"280","author":"Weichert","year":"2009","journal-title":"Cancer Lett."},{"issue":"3","key":"10.1016\/j.cca.2026.120949_bb0385","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.bbrc.2018.12.056","article-title":"YY1 negatively regulates the XAF1 gene expression in prostate cancer","volume":"508","author":"B","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"4","key":"10.1016\/j.cca.2026.120949_bb0390","article-title":"Dual inhibition of AKT-mTOR and AR signaling by targeting HDAC3 in PTEN- or SPOP-mutated prostate cancer","volume":"10","author":"Y","year":"2018","journal-title":"EMBO Mol. Med."},{"issue":"12","key":"10.1016\/j.cca.2026.120949_bb0395","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1210\/me.2009-0188","article-title":"HDAC6 regulates androgen receptor hypersensitivity and nuclear localization via modulating Hsp90 acetylation in castration-resistant prostate Cancer","volume":"23","author":"Ai","year":"2009","journal-title":"Mol. Endocrinol."},{"issue":"1","key":"10.1016\/j.cca.2026.120949_bb0400","first-page":"111","article-title":"Histone deacetylase inhibitors, valproic acid and trichostatin-a induce apoptosis and affect acetylation status of p53 in ERG-positive prostate cancer cells","volume":"39","author":"Ws","year":"2011","journal-title":"Int. J. Oncol."},{"issue":"43","key":"10.1016\/j.cca.2026.120949_bb0405","doi-asserted-by":"crossref","first-page":"4619","DOI":"10.1038\/onc.2011.612","article-title":"SIRT1 induces EMT by cooperating with EMT transcription factors and enhances prostate cancer cell migration and metastasis","volume":"31","author":"Byles","year":"2012","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.cca.2026.120949_bb0410","first-page":"1","article-title":"Cytostatic action of novel histone deacetylase inhibitors in androgen receptor-null prostate Cancer cells","volume":"14","author":"Z","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"10.1016\/j.cca.2026.120949_bb0415","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4103\/abr.abr_142_19","article-title":"Histone deacetylases and histone deacetylase inhibitors: molecular mechanisms of action in various cancers","volume":"8","author":"Sanaei","year":"2019","journal-title":"Adv. Biomed. Res."},{"key":"10.1016\/j.cca.2026.120949_bb0420","unstructured":"N. Tsuis, M. Kobayashi, K. Nagashima, Y. Wakisaka, and K. Koizumi, \u201cA new antifungal antibiotic, trichostatin\u201d."},{"issue":"6","key":"10.1016\/j.cca.2026.120949_bb0425","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1177\/1756287215597637","article-title":"Histone deacetylase inhibitors in castration-resistant prostate cancer: molecular mechanism of action and recent clinical trials","volume":"7","author":"D","year":"2015","journal-title":"Ther. Adv. Urol."},{"issue":"1","key":"10.1016\/j.cca.2026.120949_bb0430","article-title":"Epigenetic regulation of TP53 is involved in prostate cancer radioresistance and DNA damage response signaling","volume":"8","author":"Macedo-Silva","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"21","key":"10.1016\/j.cca.2026.120949_bb0435","doi-asserted-by":"crossref","first-page":"5222","DOI":"10.1016\/j.bmcl.2016.09.058","article-title":"Targeting prostate cancer with compounds possessing dual activity as androgen receptor antagonists and HDAC6 inhibitors","volume":"26","author":"Jadhavar","year":"2016","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"issue":"105","key":"10.1016\/j.cca.2026.120949_bb0440","doi-asserted-by":"crossref","first-page":"103178","DOI":"10.1039\/C6RA21271A","article-title":"Design, synthesis and biological evaluation of 2-amino-N-(2- aminophenyl)thiazole-5-carboxamide derivatives as novel Bcr-Abl and histone deacetylase dual inhibitors","volume":"6","author":"Chen","year":"2016","journal-title":"RSC Adv."},{"key":"10.1016\/j.cca.2026.120949_bb0445","doi-asserted-by":"crossref","DOI":"10.1002\/cbdv.201800027","article-title":"Quinazoline-based hydroxamic acids: design, synthesis, and evaluation of histone deacetylase inhibitory effects and cytotoxicity","author":"Hieu","year":"2018","journal-title":"Chem. Biodivers."},{"issue":"4","key":"10.1016\/j.cca.2026.120949_bb0450","doi-asserted-by":"crossref","first-page":"311","DOI":"10.4155\/fmc-2019-0290","article-title":"Discovery of class i histone deacetylase inhibitors based on romidpesin with promising selectivity for cancer cells","volume":"12","author":"Zhang","year":"2020","journal-title":"Future Med. Chem."},{"issue":"4","key":"10.1016\/j.cca.2026.120949_bb0455","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s10637-015-0252-4","article-title":"A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195","volume":"33","author":"Eigl","year":"2015","journal-title":"Invest. New Drugs"},{"issue":"1","key":"10.1016\/j.cca.2026.120949_bb0460","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1158\/1078-0432.CCR-18-1589","article-title":"Epigenetic therapy with panobinostat combined with bicalutamide rechallenge in castration-resistant prostate cancer","volume":"25","author":"Ferrari","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.cca.2026.120949_bb0465","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00280-013-2224-8","article-title":"A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer","volume":"72","author":"Rathkopf","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"15_suppl","key":"10.1016\/j.cca.2026.120949_bb0470","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1200\/jco.2009.27.15_suppl.5064","article-title":"Phase Ib dose finding trial of intravenous panobinostat with docetaxel in patients with castration-resistant prostate cancer (CRPC)","volume":"27","author":"Rathkopf","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"23","key":"10.1016\/j.cca.2026.120949_bb0475","doi-asserted-by":"crossref","first-page":"5541","DOI":"10.1002\/cncr.24597","article-title":"Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute trial 6862)","volume":"115","author":"Bradley","year":"2009","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.cca.2026.120949_bb0480","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/annonc\/mdp270","article-title":"Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)","volume":"21","author":"Molife","year":"2010","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"12","key":"10.1016\/j.cca.2026.120949_bb0485","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/onco.13957","article-title":"Phase I study of Entinostat in combination with enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer","volume":"26","author":"Lin","year":"2021","journal-title":"Oncologist"},{"issue":"15","key":"10.1016\/j.cca.2026.120949_bb0490","doi-asserted-by":"crossref","first-page":"5152","DOI":"10.1200\/jco.2008.26.15_suppl.5152","article-title":"A phase I study of oral panobinostat (LBH589) alone and in combination with docetaxel (doc) and prednisone in castration-resistant prostate cancer (CRPC)","volume":"26","author":"Rathkopf","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.cca.2026.120949_bb0495","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s10637-010-9503-6","article-title":"Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies","volume":"30","author":"Schneider","year":"2012","journal-title":"Invest. New Drugs"},{"issue":"15_suppl","key":"10.1016\/j.cca.2026.120949_bb0500","doi-asserted-by":"crossref","first-page":"5017","DOI":"10.1200\/jco.2013.31.15_suppl.5017","article-title":"Sulforaphane treatment in men with recurrent prostate cancer","volume":"31","author":"Alumkal","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.cca.2026.120949_bb0505","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1080\/01635581.2019.1619783","article-title":"Sulforaphane bioavailability and Chemopreventive activity in men presenting for biopsy of the prostate gland: a randomized controlled trial HHS public access","volume":"72","author":"Zhang","year":"2020","journal-title":"Nutr. Cancer"},{"issue":"6","key":"10.1016\/j.cca.2026.120949_bb0510","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/pros.23766","article-title":"A randomized, double-blind, placebo-controlled trial to evaluate the role of curcumin in prostate cancer patients with intermittent androgen deprivation","volume":"79","author":"Choi","year":"2019","journal-title":"Prostate"},{"issue":"2","key":"10.1016\/j.cca.2026.120949_bb0515","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000441148","article-title":"The new combination docetaxel, prednisone and curcumin in patients with castration-resistant prostate cancer: a pilot phase II study","volume":"90","author":"Mahammedi","year":"2016","journal-title":"Oncology"},{"issue":"7","key":"10.1016\/j.cca.2026.120949_bb0520","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1002\/cam4.3806","article-title":"Multicenter randomized phase II study comparing docetaxel plus curcumin versus docetaxel plus placebo in first-line treatment of metastatic castration-resistant prostate cancer","volume":"10","author":"Passildas-Jahanmohan","year":"2021","journal-title":"Cancer Med."},{"issue":"2","key":"10.1016\/j.cca.2026.120949_bb0525","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1089\/jmf.2018.0024","article-title":"Isothiocyanate from broccoli, sulforaphane, and its properties","volume":"22","author":"Vanduchova","year":"2019","journal-title":"J. Med. Food"},{"issue":"8","key":"10.1016\/j.cca.2026.120949_bb0530","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1158\/1940-6207.CAPR-14-0459","article-title":"Effect of sulforaphane in men with biochemical recurrence after radical prostatectomy","volume":"8","author":"Cipolla","year":"2015","journal-title":"Cancer Prev. Res. (Phila.)"},{"issue":"7","key":"10.1016\/j.cca.2026.120949_bb0535","doi-asserted-by":"crossref","DOI":"10.3390\/ph14070670","article-title":"Hydralazine and panobinostat attenuate malignant properties of prostate cancer cell lines","volume":"14","author":"Pacheco","year":"2021","journal-title":"Pharmaceuticals"},{"issue":"12","key":"10.1016\/j.cca.2026.120949_bb0540","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1158\/1541-7786.MCR-14-0173","article-title":"Synergistic loss of prostate cancer cell viability by coinhibition of HDAC and PARP","volume":"12","author":"Chao","year":"2014","journal-title":"Mol. Cancer Res."},{"issue":"1","key":"10.1016\/j.cca.2026.120949_bb0545","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-022-02290-9","article-title":"Correction to: PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1\/. BRCA1 DNA damage repair complex in prostate cancer cells","volume":"41","author":"Yin","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.cca.2026.120949_bb0550","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s10637-017-0529-x","article-title":"Combination treatment with docetaxel and histone deacetylase inhibitors downregulates androgen receptor signaling in castration-resistant prostate cancer","volume":"36","author":"Park","year":"2018","journal-title":"Invest. New Drugs"},{"issue":"14","key":"10.1016\/j.cca.2026.120949_bb0555","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1002\/pros.21187","article-title":"An in vitro model for preclinical testing of endocrine therapy combinations for prostate cancer","volume":"70","author":"Pfeiffer","year":"2010","journal-title":"Prostate"},{"key":"10.1016\/j.cca.2026.120949_bb0560","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.00610","article-title":"Synergistic interaction of histone deacetylase 6- and MEK-inhibitors in castration-resistant prostate Cancer cells","volume":"8","author":"Corno","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"issue":"9\u201310","key":"10.1016\/j.cca.2026.120949_bb0565","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.lfs.2010.12.017","article-title":"Inhibitory effects of the HDAC inhibitor valproic acid on prostate cancer growth are enhanced by simultaneous application of the mTOR inhibitor RAD001","volume":"88","author":"Wedel","year":"2011","journal-title":"Life Sci."},{"issue":"5","key":"10.1016\/j.cca.2026.120949_bb0570","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10585-011-9386-8","article-title":"Impact of combined HDAC and mTOR inhibition on adhesion, migration and invasion of prostate cancer cells","volume":"28","author":"Wedel","year":"2011","journal-title":"Clin. Exp. Metastasis"},{"issue":"9","key":"10.1016\/j.cca.2026.120949_bb0575","doi-asserted-by":"crossref","DOI":"10.3390\/cells7090129","article-title":"HDAC inhibition counteracts metastatic re-activation of prostate cancer cells induced by chronic mTOR suppression","volume":"7","author":"Makarevi\u0107","year":"2018","journal-title":"Cells"},{"issue":"11","key":"10.1016\/j.cca.2026.120949_bb0580","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1002\/phar.2027","article-title":"A novel use of Olaparib for the treatment of metastatic castration-recurrent prostate Cancer","volume":"37","author":"Martin","year":"2017","journal-title":"Pharmacotherapy"},{"issue":"1","key":"10.1016\/j.cca.2026.120949_bb0585","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12935-022-02706-8","article-title":"Recent advances and limitations of mTOR inhibitors in the treatment of cancer","volume":"22","author":"Ali","year":"2022","journal-title":"Cancer Cell Int."}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898126001312?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898126001312?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T21:34:39Z","timestamp":1774042479000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898126001312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":117,"alternative-id":["S0009898126001312"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2026.120949","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From bench to bedside: translating the histone deacetylase inhibitors into prostate cancer therapies","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2026.120949","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"120949"}}